To investigate the effect of pristimerin on gefitinib resistance in lung cancer cells and its regulation microRNA-936. Lung cell HCC827 was cultured vitro, resistant HCC827/gefitinib established were randomly assigned to control group, pristimerin-L pristimerin-M pristimerin-H gefitinib+pristimerin gefitinib+microRNA-negative gefitinib+microRNA-936 gefitinib+pristimerin+anti-microRNA negative g...

Objective(s): Our previous study showed that a newly designed tracer radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline ([125I]PYK) is promising for the evaluation of the epidermal growth factor receptor (EGFR) status and prediction of gefitinib treatment of non-small cell lung cancer. EGFR is over-expressed and mutated also in glioblastoma. In the present study, the ...

Background: Usually, chemoradiotherapy can be used for the treatment of locally advanced colorectal cancer (CRC) before surgery. On the other hand, some studies have shown that fractional radiation of tumor cells leads to chemoresistance. The aim of this study was to evaluate the chemoresistance of radioresistant sub-line (RR sub-line).Methods: This study was done in Hamadan University of...

objective(s): our previous study showed that a newly designed tracer radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline ([125i]pyk) is promising for the evaluation of the epidermal growth factor receptor (egfr) status and prediction of gefitinib treatment of non-small cell lung cancer. egfr is over-expressed and mutated also in glioblastoma. in the present study,...

To gain an insight into the molecular mechanisms of gefitinib resistance in nonsmall cell lung cancer, we screened out long noncoding RNA related to through microarray data gefitinib-sensitive and resistant cells. lncRNA ZMIZ1-AS1 was significantly upregulated HCC827/GR cells by screening data. Further real-time-qPCR results were consistent with Cell viability assay flow cytometry showed that i...

For non-small cell lung cancer (NSCLC) treatment, a BCS class II drug, Gefitinib, was widely used. Due to poor bioavailability, uncontrollable drug release, Gefitinib witnessed side effects. To circumvent such associated problems, optimized encapsulated polycaprolactone (PCL) nanoparticles with three different molecular weights of PCL (average Mn?10,000, Mn?45,000 & Mn?80,000) were developed us...

People’s lives and health are gravely threatened by non-small-cell lung cancer (NSCLC). Mutations in epidermal growth factor receptor (EGFR), a transmembrane tyrosine kinase, considered one of the causes NSCLC. Tyrosine kinase inhibitors (TKIs) typically used to treat patients with EGFR mutations. In this study, Gefitinib, member first generation TKIs, was an single-point mutation (single mutan...

Gefitinib, the epidermal growth factor receptor tyrosine kinase inhibitor, is effective for patients with non-small cell lung cancer. However, a serious adverse effect, interstitial lung disease (ILD), has been reported. The re-administration of gefitinib might be considered when there is no other choice of treatment and a therapeutic effect can be expected; however, there is no published data ...

Therapies that target the EGF receptor (EGFR), such as gefitinib (IRESSA), are effective in a subset of patients with advanced non-small cell lung cancer (NSCLC). The differences in intracellular signaling networks between gefitinib-sensitive and -resistant NSCLCs remain poorly understood. In this study, we observe that gefitinib reduces phospho-Akt levels only in NSCLC cell lines in which it i...

The role of epithelial-to-mesenchymal transition in cancer drug resistance is increasingly acknowledged. We examined whether epithelial-to-mesenchymal transition affects gefitinib resistance in non-small cell lung cancer (NSCLC) cells. Cell viability was detected by CCK-8 assay, VIM expression levels were determined by quantitative real-time polymerase chain reaction. Western blot and immunocyt...